Key takeaway: Jeena Sikho Lifecare Limited (JSLL) submitted an investor presentation on August 9, 2026, detailing its financial performance for the quarter ended June 30, 2026. The presentation highlighted a 29% year-on-year increase in revenue from operations, attributed to higher patient footfalls and an expanding service network. EBITDA grew by 17% year-on-year, with a margin of 41%. The Ayurveda Healthcare Products segment reported a 47% year-on-year growth, supported by a broader product portfolio. The company noted strong demand in its Ayurveda Healthcare Services, with a 13% increase in Panchkarma revenue and a 31% rise in day care volumes. JSLL operates approximately 2,400 beds and plans to expand its network to enhance treatment capacity. The document emphasized the company's commitment to leveraging its healthcare ecosystem for growth and cross-selling opportunities.

Key takeaway: Jeena Sikho Lifecare Limited (JSLL) held its earnings conference call on June 2, 2026, to discuss its financial results for Q4 and FY26. Management highlighted a significant year-on-year revenue growth of 71%, reaching INR 801 crores, with a PAT increase of 177% to INR 222 crores. The company emphasized its unique business model focused on preventive healthcare through Ayurveda, operating 58 hospitals and 59 clinical centers across India. Management reported a 65% increase in IPD patient volume and a 69% increase in OPD patient volume. They outlined plans to expand operational beds from 2,300 to 3,000 in the next few months, with a long-term goal of 7,000 to 10,000 beds. Management also discussed the launch of the Jeena Sikho Swadeshi Health Card and ongoing international expansion efforts. Despite some one-time financial adjustments impacting Q4 results, management expressed confidence in sustainable growth and profitability.

Key takeaway: On June 1, 2026, Jeena Sikho Lifecare Limited submitted a revised investor presentation to the National Stock Exchange of India and BSE, updating previous communications regarding a conference call to discuss the company's financial performance for Q4 and the fiscal year ending March 31, 2026. The revision included updates and clarifications to the earlier presentation shared on May 31, 2026. The presentation highlighted significant financial growth, with revenue from operations increasing by 71% year-over-year for FY26, driven by higher patient volumes and an expanding product portfolio. The company reported an EBITDA margin improvement to 44% for FY26, reflecting operational leverage and scalability. Additionally, the presentation detailed the launch of the Jeena Sikho Health Card aimed at enhancing patient loyalty. The document also noted the company's commitment to rewarding shareholders with a proposed final dividend of Rs. 4.50 per equity share, pending shareholder approval.

Key takeaway: Jeena Sikho Lifecare Limited (JSLL) submitted an investor presentation on May 31, 2026, detailing its financial performance for Q4 and the fiscal year ending March 31, 2026. The presentation highlighted a 55% year-over-year increase in revenue from operations, attributed to higher patient volumes and an expanding service reach. EBITDA margins were reported at 36%, with a noted sequential decline due to increased provisions related to labor code amendments and performance bonuses. The Ayurveda Healthcare Services segment saw a 52% revenue growth for FY26, with significant increases in both inpatient and outpatient volumes. The company also launched the Jeena Sikho Health Card to enhance patient loyalty. The Board of Directors proposed a final dividend of Rs. 4.50 per equity share for FY26, pending shareholder approval. The presentation emphasized the company's commitment to holistic health and wellness through Ayurveda.

Key takeaway: During the earnings conference call held on February 9, 2026, Jeena Sikho Lifecare Limited reported strong financial and operational performance for Q3 FY '26. Management highlighted a total operational income of INR 221.7 crores, marking a 92% year-on-year increase. EBITDA reached INR 100.8 crores, a 240% rise from the previous year, with a margin of over 45%. Profit after tax was INR 66.7 crores, reflecting a 400% increase year-on-year. The call emphasized growth in both service and product segments, with significant increases in patient consultations and product sales. Management discussed plans for expanding bed capacity and launching new products, including the Jeena Sikho Health Card aimed at enhancing patient engagement. The company also noted its focus on research, with approximately 180 research papers published. Overall, management expressed confidence in sustaining growth and improving operational efficiency despite ongoing investments in expansion.

Key takeaway: The investor presentation from Jeena Sikho Lifecare Limited (JSLL) dated February 8, 2026, outlines the company's financial performance for Q3 FY 2025-26. Management reported a significant year-on-year revenue growth of 92%, reaching ₹221.66 crore, with EBITDA margins remaining strong at 45%. The presentation highlighted robust patient volumes across both inpatient and outpatient departments, contributing to increased service revenue. Management noted the ongoing development of 475+ beds, enhancing capacity for future growth. The company emphasized its commitment to Ayurveda and holistic health, showcasing a diversified product portfolio and successful recent launches. The document also detailed the company's operational expansion across India, with 120+ clinics and hospitals, and a focus on enhancing customer engagement through initiatives like the Jeena Sikho Health Card. Overall, the presentation reflected a strong operational performance and strategic growth initiatives.